BCL6-IN-8c is primarily used in research settings to study its effects on B-cell lymphoma 6 (BCL6) protein, which plays a critical role in the development of certain cancers, particularly diffuse large B-cell lymphoma (DLBCL). It functions as a potent inhibitor of BCL6, disrupting its interaction with co-repressors and thereby reducing its oncogenic activity. This chemical is valuable in preclinical studies aimed at understanding the molecular mechanisms of BCL6 in cancer progression and in evaluating its potential as a therapeutic target. Researchers also use BCL6-IN-8c to explore its efficacy in combination with other anticancer agents, aiming to develop more effective treatment strategies for BCL6-dependent malignancies. Its application is largely confined to laboratory experiments and drug discovery efforts, contributing to the development of novel cancer therapies.